EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia

Kun Yang, Beibei Yang, Yali Zhou, Qiuying Huang, Xiaolin Yin

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06312-2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Kun Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zigong First People's Hospital, Zigong, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Triazoles, Hydrazines, fms-Like Tyrosine Kinase 3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nucleoporin 98 (NUP98) fusion oncoproteins are associated with various hematologic malignancies. Acute myeloid leukemia (AML) with NUP98-NSD1 typically co-occurs with FLT3-ITD mutations, exhibiting poor initial responses to traditional chemotherapy. This case report describes a relapsed and refractory AML case co-expressing NUP98/NSD1 and FLT3/ITD after matched sibling haplo-identical allogeneic hematopoietic stem cell transplantation, achieving molecular remission with a salvage therapy combining selinexor, venetoclax, and azacitidine. To our knowledge, this is the first report demonstrating the effectiveness of this combination therapy for relapsed/refractory NUP98-NSD1+/FLT3-ITD + AML. This report highlights the potential synergy between selinexor and established AML therapies, suggesting a promising approach to improve outcomes for refractory AML patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTriazolesHydrazinesfms-Like Tyrosine Kinase 3Nuclear Pore Complex ProteinsOncogene Proteins, FusionHumansBridged Bicyclo Compounds, HeterocyclicHematopoietic Stem Cell TransplantationMaleAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyAzacitidineSulfonamidesMiddle Aged

Stichwörter der Autor:innen

Acute myeloid leukemiaFIT3-ITDHematopoietic stem cell transplantationNUP98-NSD1Selinexor

Substanzen

TriazolesHydrazinesselinexorfms-Like Tyrosine Kinase 3FLT3 protein, humanBridged Bicyclo Compounds, HeterocyclicNuclear Pore Complex ProteinsOncogene Proteins, FusionNUP98-NSD1 protein, humanvenetoclax

Autor:innen und Institutionen

  • Department of Hematology, Zigong First People's Hospital, Zigong, China.
  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army, Nanning, Guangxi, China.
  • Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army, Nanning, Guangxi, China. yin-xl@163.com.

Zitieren

APA

Yang, K., Yang, B., Zhou, Y., Huang, Q., & Yin, X. (2025). Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-025-06312-2

Vancouver

Yang K, Yang B, Zhou Y, Huang Q, Yin X. Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06312-2

BibTeX
@article{Yang2025,
  author = {Yang, Kun and Yang, Beibei and Zhou, Yali and Huang, Qiuying and Yin, Xiaolin},
  title = {Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06312-2}
}
Kostenlos starten →